Loading organizations...
Loading organizations...
Clinical-stage biotech developing therapeutics for CLDN1+ cancers.
Alentis Therapeutics has raised $365.4M across 4 funding rounds.
Alentis Therapeutics has raised $365.4M in total across 4 funding rounds.
Alentis Therapeutics has raised $365.4M in total across 4 funding rounds.
Alentis Therapeutics's investors include Jeito Capital, Novo Holdings, OrbiMed, Morningside, BioMedPartners, Pureos Bioventures.
Alentis Therapeutics has raised $365.4M across 4 funding rounds. Most recently, it raised $181.4M Series D in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 12, 2024 | $181.4M Series D | Jeito Capital, Novo Holdings, OrbiMed | |
| Apr 13, 2023 | $105.0M Series C | Jeito Capital, Novo Holdings | |
| Jun 15, 2021 | $66.7M Series B | Morningside | |
| May 1, 2019 | $12.3M Series A | BioMedPartners, Pureos Bioventures |